Five things for pharma marketers to know: Thursday, April 26, 2018

Share this content:

Acadia Pharmaceuticals' only drug is being re-examined by the FDA after reports surfaced of patients dying while taking it. Nuplazid treats symptoms associated with Parkinson's disease such as hallucinations and psychosis. Shares plunged after the FDA report was released on Wednesday. (CNN)


Koch-backed group Americans for Prosperity is launching an ad campaign in support of “right-to-try” legislation. The effort includes digital and TV ads pushing for access to experimental therapies for terminally ill patients. (STAT)


Juno Therapeutics cofounder and CEO Hans Bishop has left the company following its acquisition by Celgene. He is sitting on Celgene's board of directors. Celgene bought Juno for $9 billion in January. (GeekWire)


The FDA is promoting the use of artificial intelligence in medicine by expanding its digital health program and health technology incubator, the Information Exchange and Data Transformation. FDA commissioner Scott Gottlieb stated that the agency is focusing on tools for cancer treatment and drug development. (CNBC)


AbbVie's late-stage rheumatoid arthritis drug, upadacitinib, has shown positive data in Phase IIB/III study. The company also submitted a biologics license application for risankizumab, a treatment for severe plaque psoriasis. (Endpoints)


Share this content:
Scroll down to see the next article